The Board of Directors of Instadose Pharma Corp. announced that effective January 14, 2022, they have accepted the planned resignation of Grant F. Sanders as Chairman and CEO of Instadose US and as Chairman of its wholly owned Canadian subsidiary ("Instadose Canada"). Mr. Sanders will not hold any officer or director positions at Instadose US or Instadose Canada following his resignation.

Alex Wylie will assume the role of interim Chairman of Instadose US, and interim CEO of Instadose US and Instadose Canada Mr. Wylie will continue in his role as CFO of Instadose US and Instadose Canada. Instadose US' Board of Directors will initiate a process to find a permanent Chairman and CEO of Instadose US. Alex Wylie will be a potential candidate for the role of CEO and/or Chairman.

Ed Borkowski has decided not to accept the position of CEO of Instadose Canada and instead agreed to assume the position as Vice Chairman of Instadose Canada. He will advise and guide the organization as it continues its transition into the US public markets.